Related Experiment Videos
Aspirin versus anticoagulation in intra- and extracranial vertebral artery dissection
1Stroke Clinic, National Institute of Neurology and Neurosurgery Manuel Velasco Suárez, México City (DF), México. antonio.arauz@prodigy.net.mx
Insights
Recurrent ischaemic stroke is rare in patients with vertebral artery dissection (VAD) treated with aspirin or oral anticoagulation. The choice of antithrombotic therapy did not significantly impact outcomes or bleeding complications.
Area of Science:
- Neurology
- Vascular Medicine
- Cardiology
Background:
- Vertebral artery dissection (VAD) is a significant cause of stroke in younger adults.
- Antithrombotic therapy is standard, but optimal choice between aspirin and oral anticoagulation (OA) remains debated.
- Understanding recurrent event rates and adverse events is crucial for patient management.
Purpose of the Study:
- To determine the incidence and predictors of recurrent ischaemic stroke after a first VAD.
- To evaluate adverse events associated with aspirin versus OA in VAD patients.
- To assess the impact of antithrombotic choice on functional outcomes.
Main Methods:
- Retrospective analysis of a 21-year database of 110 patients with confirmed VAD (first-ever ischaemic stroke).
- Patients were treated with either aspirin or oral anticoagulation (OA).
- Outcomes included recurrent ischaemic events and major bleeding; functional outcome assessed using modified Rankin score.
Main Results:
- Recurrent ischaemic events were rare (one case) during follow-up.
- No significant difference in baseline characteristics or outcomes between aspirin and OA groups.
- No bleeding complications were reported; good functional outcome (mRS ≤ 2) in 82 patients.
Conclusions:
- The frequency of recurrent ischaemic stroke in VAD patients appears low.
- Antithrombotic treatment choice (aspirin vs. OA) did not influence outcomes or bleeding risk in this cohort.
- Further non-randomized studies support the safety and efficacy of both aspirin and OA for VAD management.
Background And Purpose:
To evaluate the incidence and predictors of ischaemic recurrent stroke and the adverse events of antithrombotic therapy in patients with first intra- or extracranial vertebral artery dissection (VAD) who were treated with aspirin or oral anticoagulation (OA).
Methods:
A 21-year database of consecutive patients with confirmed diagnoses of VAD (n = 110, 63% men; mean age 37.9 ± 8.5 years) without intracerebral hemorrhage and who were treated with aspirin or OA were analyzed retrospectively. In all cases, the admission diagnosis was ischaemic stroke. Three groups were defined according to the site of the dissection: (i) extracranial, (ii) intracranial, and (iii) intra-/extracranial. Clinical follow-up was obtained by neurologic examination. Outcome measures were (i) recurrent ischaemic events (ischaemic stroke or transient ischaemic attack) and (ii) intra- and extracranial major bleeding.
Results:
No difference in age, smoking, or hypertension was found between patients treated with OA (n = 49) and those treated with aspirin (n = 50). Extracranial artery dissection (49%) had preponderance over intracranial (27%) or intra-/extracranial (23%) location. During the follow-up, recurrent ischaemic events were rare (one case). There were no bleeding complications. The treatment that was used did not influence the functional outcome or recanalization. A good functional outcome (modified Rankin score ≤ 2) was observed in 82 patients.
Conclusions:
Although this was a non-randomized study, our data suggest that the frequency of recurrent ischaemic stroke in patients with intra- or extracranial VAD is low and most likely independent of the type of antithrombotic treatment.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...